USFDA3 Jun 2026, 10:32 am
Zydus Lifesciences Receives USFDA Warning Letter for Baddi Facility
AI Summary
Zydus Lifesciences Ltd announced it has received a Warning Letter from the USFDA concerning its Baddi facility. The letter relates to technical observations on the use of purified talc not meeting USP requirements and was issued following a request for records, not an on-site inspection. The company believes this will not impact current operations or supplies from the site. The Baddi facility's last USFDA inspection in August 2025 resulted in a Voluntary Action Indicated (VAI) status. Zydus is committed to addressing the remediation steps promptly.
Key Highlights
- USFDA issues Warning Letter for Zydus' Baddi facility.
- Letter concerns purified talc not meeting USP requirements.
- No on-site inspection preceded the Warning Letter.
- Company expects no impact on current operations or supplies.
- Zydus committed to prompt remediation and USFDA cooperation.
Price Impact
More from ZYDUSLIFE